InMed Pharmaceuticals (INM) Non-Current Assets (2020 - 2026)

InMed Pharmaceuticals' Non-Current Assets history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 21.75% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 18.8% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 13.42% from the prior year.
• Non-Current Assets slipped to $2.2 million in Q1 2026 per INM's latest filing, from $2.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $6.7 million in Q1 2022 and bottomed at $2.2 million in Q1 2026.
• The 5-year median for Non-Current Assets is $2.9 million (2022), against an average of $3.1 million.
• Biggest YoY gain for Non-Current Assets was 365.3% in 2022; the steepest drop was 57.81% in 2022.
• Year by year, Non-Current Assets stood at $2.9 million in 2022, then gained by 18.73% to $3.4 million in 2023, then retreated by 11.99% to $3.0 million in 2024, then fell by 20.76% to $2.4 million in 2025, then slipped by 6.54% to $2.2 million in 2026.
• Per Business Quant, the three latest INM Non-Current Assets figures stand at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.6 million (Q3 2025).